October 1, 2022 10:22 AM EDTUpdated October 3, 07:30 AM

#AAO22: J&J’s first look at common eye disease portfolio pads the case for PhII of gene therapy

Kyle LaHucik

Senior Reporter

CHICAGO — While the later-stage drug developers in the geographic atrophy field are near the finish line, Johnson & Johnson’s Janssen is taking a more …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#AAO22: J&J’s first look at common eye disease portfolio pads the case for PhII of gene therapy

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Where the money is: The top 100 venture investors in biotech

J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar

Lilly pays $10M upfront for Organovo’s FXR agonist program

Compounders sue FDA over removal of semaglutide from official shortage list

Candel's viral therapy shows promising survival in small pancreatic cancer study

How AI can address ongoing challenges in the life sciences industry

#AAO22: J&J’s first look at com­mon eye dis­ease port­fo­lio pads the case for PhII of gene ther­a­py

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

#AAO22: J&J’s first look at common eye disease portfolio pads the case for PhII of gene therapy